Prof. Dr. Frank Stangenberg Haverkamp, Merck Foundation Board of Trustees emphasized, "Our aim is to improve the overall health and wellbeing of people by building healthcare capacity across Africa, ...
To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most ...
Dr. Rasha Kelej and Cabo Verde First Lady sign Memorandum of Understanding (MoU) to underscores their long-term partnership to strengthen healthcare capacity ...
JPMorgan lowered the firm’s price target on Merck KGaA (MKKGY) to EUR 150 from EUR 155 and keeps an Overweight rating on the shares. Published ...
As of Friday, December 12, Nektar Therapeutics’s NKTR share price has surged by 8.51%, which has investors questioning if ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...
Firms with significant exposure to federal spending, government contracts and regulatory approvals are now tallying up the ...
The global lateral flow assay (LFA) components market is poised for significant growth, projected to reach USD 486.2 million ...
Dr. Rasha Kelej highlighted the deepening collaboration between Merck Foundation and Cabo Verde, announcing that young ...
According to MarketsandMarkets™, the Pharmaceutical Filtration Market is projected to grow from about USD 14.35 billion in ...
RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...
In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback